Clinical Trials Browser

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled 1 FDA

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

60 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03795207 2026-03-31

POSTCARD

Phase 2 Active not recruiting

96 enrolled

Genitourinary

Node; Prostate

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Genitourinary

Carcinoma, Transitional Cell

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

VOLGA

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

NILE

PATAPSCO

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

SAMETA

GCND

BAYOU

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

RESOLVE

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

ADAPT-BLADDER

POTOMAC

ENHANCE

POSTCARD

IMAGINE

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)